ArticleBiomacromolecules2026
Orthogonal Chemistry Enables Precision Nanoparticle Cofunctionalization for Tuning Immune Stimulation and Antigen Presentation.
Article in Biomacromolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Combination therapies are increasingly utilized to treat complex diseases, capitalizing on drug synergies to potentiate overall therapeutic responses and improve patient outcomes. Drug delivery systems improve combination therapy access to tissues and cells of interest, but attempting to coconjugate multiple drugs to the same carrier can limit the precision of drug ratios or release behaviors, making it challenging to optimize the delivery of the individual drug compounds. Here, thiol-disulfide exchange and strain-promoted click chemistry are leveraged in combination with an established polymeric nanoparticle platform to achieve chemistry-defined control over both the conjugation ratio and release behavior of coconjugated moieties. When applied as a subunit vaccine platform, this system enables the modulation of lymph node dendritic cell maturation and antigen presentation. The results presented here thus demonstrate a versatile dual-functional drug delivery platform to overcome existing challenges in combination therapy delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.